| Title: |
PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| Authors: |
Chen, C.; Gasparetto, C.; White, D.; Kotb, R.; Lipe, B.; Sutherland, H.; Sebag, M.; Tuchman, S.; Baljevic, M.; Bensinger, W.; LeBlanc, R.; Venner, C.; Lentzsch, S.; Schiller, G.; Callander, N.; Rodriguez‐Lopez, K.; Sheehan, H.; Saint‐Martin, J.‐R.; Shah, J.; Shacham, S.; Kauffman, M.; Bahlis, N. |
| Source: |
HemaSphere ; volume 3, issue S1, page 245 ; ISSN 2572-9241 2572-9241 |
| Publisher Information: |
Wiley |
| Publication Year: |
2019 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Background: The nuclear export protein Exportin 1 (XPO1) is overexpressed in a wide variety of cancers including multiple myeloma (MM) and associated with poor prognosis. Selinexor is a first‐in‐class Selective Inhibitor of Nuclear Export (SINE) compound that selectively binds and inactivates XPO1, therefore forces the nuclear retention and re‐activation of cell cycle regulators such as p53, FOXO, IkB, and Rb. Pomalidomide/dexamethasone (Pd) achieved an overall response rate (ORR) of 31% and progression‐free survival (PFS) rate of |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1097/01.hs9.0000560636.62389.3a |
| DOI: |
10.1097/01.HS9.0000560636.62389.3a |
| Availability: |
https://doi.org/10.1097/01.hs9.0000560636.62389.3a; https://onlinelibrary.wiley.com/doi/pdf/10.1097/01.HS9.0000560636.62389.3a |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.B4A8C2C1 |
| Database: |
BASE |